Skip to Content

Posts tagged with "Clinical Trials"

  • Cancer

    Bind’s Attempts To Remake Chemotherapy

    There’s a lot of effort (and a lot of money) going into targeted nanoparticle drug delivery. And that’s completely understandable, because the way we dose things now, with any luck, will eventually come to seem primitive. So you used to just have people eat the compound, did you, or just poke it into their bloodstream… Read More
  • Clinical Trials

    Wait, We Didn’t Tell You About That Endpoint?

    Hmm. Via Twitter, we find this interesting example of moving the goalposts. NeoStem, a small stem-cell company, announced results the other day for a trial of their cardiac stem cell therapy. One bearish trader who’d been following them was surprised that the stock didn’t drop more on the results, given that the trial didn’t seem… Read More
  • Cardiovascular Disease

    Vytorin Actually Works

    The data from the IMPROVE-IT trial on cardiovascular outcomes for Vytorin have been released. And the combination met the primary endpoint: fewer heart attacks and strokes compared to those already on statin therapy alone. Matthew Herper has an excellent roundup of the results and their context. The effect is real, but it’s not gigantic, eith… Read More
  • Cardiovascular Disease

    Remember Vytorin? The Data Are Finally Coming.

    If you follow cardiovascular therapies, you’ll no doubt have seen that a bit of information has come out on Merck’s long, long, long-running IMPROVE-IT trial. That is the massive outcomes study for Vytorin, the combination of ezetimibe (the Schering-Plough cholesterol absorption inhibitor) and simvastatin (Merck’s early statin dru… Read More
  • Cancer

    The Drug Worked, Unfortunately

    There’s an old story of a guy who lost three cars by betting on inside straights in poker games. He lost the first two when he drew and didn’t fill the hand – and he lost the third one when he did. In other words, you need to be sure that even if things work… Read More
  • Animal Testing

    Near-Animal, Near-Human: The Future of Drug Testing?

    Here’s a good article on animal models in drug discovery, and their many limitations. We have moved away from studying human disease in humans,” (Elias) Zerhouni lamented to the NIH’s Scientific Review Management Board meeting. “We all drank the Kool-Aid on that one, me included.” “The problem is that it hasn’t worked, and it’s… Read More
  • Clinical Trials

    Clinical Trials in Ebola

    So with various Ebola vaccines and therapies in development, how exactly are the necessary clinical trials going to be run? That’s always a tricky business with an infectious disease that comes and goes – the current Ebola outbreak is by far the largest yet seen, but there are years when no cases are reported at… Read More
  • Business and Markets

    Novo Nordisk Braves the Obesity Market

    Everyone thinks of Novo Nordisk as a diabetes company (and that they are), but they’re willing to use their expertise in related areas. And if you know a lot about insulin and blood sugar regulation, you may also end up knowing a fair amount about appetite and satiety signaling in the gut. The company has… Read More
  • Cancer

    Nivolumab Racks Up Another Success

    I’m always happy to highlight impressive clinical data, and this is impressive. Bristol-Myers Squibb’s nivolumab (which has been doing very well in clinical trials so far) apparently has very significant effects in refractory squamous cell lung cancer as well. 41% of the patients on the drug in the latest study are alive at the one-year… Read More
  • Cancer

    Aileron Heads Toward the Clinic

    Aileron, the stapled-peptide company, has had its ups and downs over the past few years. They went through the typical cut-back-hard phase not too long ago, but have been rounding up more money to try out their p53-targeted idea (blogged on here). I’m glad to hear it. I would really like to see how some… Read More